Treatment of diabetic macular oedema (DME) with ranibizumab may improve retinal function and structure, according to researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College, London Institute of Ophthalmology.
Treatment of diabetic macular oedema (DME) with ranibizumab may improve retinal function and structure, according to researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College, London Institute of Ophthalmology.
They conducted this prospective, randomized, single-masked clinical trial in 33 eyes of 33 patients with centre-involved DME, with BCVA of 55 to 79, as measured by the Early Treatment Diabetic Retinopathy Study letters at baseline. For this 48-week study, patients were randomized 2:1 to treatment with ranibizumab (with three loading doses followed by one re-treatment as required) or macular laser therapy (at baseline and repeated as needed every 12 weeks).
Patients treated with ranibizumab gained 6.0 letters compared with 0.9 letters lost for laser. They also showed improved tritan and protan colour contrast thresholds and improved retinal sensitivity and electrophysiologic function. Patients in the ranibizumab treatment group also exhibited retinal thickness reduction and structural improvement in optical coherence tomography features of DME, compared with those in the laser treated group. Finally, in patients treated with ranibizumab, no evidence of progressive ischaemia was seen.
To view the abstract of this study, published in the American Journal of Ophthalmology, click here.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials